| . | Arm A . | Arm B . |
|---|---|---|
| (n = 51) | (n = 49) | |
| Age (years) | ||
| Median (range) | 65 (38–78) | 67 (28–80) |
| Gender, n (%) | ||
| Male | 22 (43) | 23 (47) |
| Female | 29 (57) | 26 (53) |
| ECOG PS, n (%) | ||
| 0 | 35 (69) | 28 (57) |
| 1 | 16 (31) | 21 (43) |
| Tumor location, n (%) | ||
| Head | 29 (57) | 25 (51) |
| Body or tail | 22 (43) | 24 (49) |
| Nodal statusa, n (%) | ||
| N0 | 40 (78) | 36 (73) |
| N1 | 11 (22) | 13 (27) |
| Biliary drainage, n (%) | ||
| No | 36 (71) | 35 (71) |
| Yes | 15 (29) | 14 (29) |
| CA19-9 (IU/ml), n (%) | ||
| < 1000 | 39 (76) | 37 (76) |
| ≥ 1000 | 12 (24) | 12 (24) |
| . | Arm A . | Arm B . |
|---|---|---|
| (n = 51) | (n = 49) | |
| Age (years) | ||
| Median (range) | 65 (38–78) | 67 (28–80) |
| Gender, n (%) | ||
| Male | 22 (43) | 23 (47) |
| Female | 29 (57) | 26 (53) |
| ECOG PS, n (%) | ||
| 0 | 35 (69) | 28 (57) |
| 1 | 16 (31) | 21 (43) |
| Tumor location, n (%) | ||
| Head | 29 (57) | 25 (51) |
| Body or tail | 22 (43) | 24 (49) |
| Nodal statusa, n (%) | ||
| N0 | 40 (78) | 36 (73) |
| N1 | 11 (22) | 13 (27) |
| Biliary drainage, n (%) | ||
| No | 36 (71) | 35 (71) |
| Yes | 15 (29) | 14 (29) |
| CA19-9 (IU/ml), n (%) | ||
| < 1000 | 39 (76) | 37 (76) |
| ≥ 1000 | 12 (24) | 12 (24) |
ECOG PS, Eastern Cooperative Oncology Group performance status.
aAccording to the Union for International Cancer Control TNM version 7.
| . | Arm A . | Arm B . |
|---|---|---|
| (n = 51) | (n = 49) | |
| Age (years) | ||
| Median (range) | 65 (38–78) | 67 (28–80) |
| Gender, n (%) | ||
| Male | 22 (43) | 23 (47) |
| Female | 29 (57) | 26 (53) |
| ECOG PS, n (%) | ||
| 0 | 35 (69) | 28 (57) |
| 1 | 16 (31) | 21 (43) |
| Tumor location, n (%) | ||
| Head | 29 (57) | 25 (51) |
| Body or tail | 22 (43) | 24 (49) |
| Nodal statusa, n (%) | ||
| N0 | 40 (78) | 36 (73) |
| N1 | 11 (22) | 13 (27) |
| Biliary drainage, n (%) | ||
| No | 36 (71) | 35 (71) |
| Yes | 15 (29) | 14 (29) |
| CA19-9 (IU/ml), n (%) | ||
| < 1000 | 39 (76) | 37 (76) |
| ≥ 1000 | 12 (24) | 12 (24) |
| . | Arm A . | Arm B . |
|---|---|---|
| (n = 51) | (n = 49) | |
| Age (years) | ||
| Median (range) | 65 (38–78) | 67 (28–80) |
| Gender, n (%) | ||
| Male | 22 (43) | 23 (47) |
| Female | 29 (57) | 26 (53) |
| ECOG PS, n (%) | ||
| 0 | 35 (69) | 28 (57) |
| 1 | 16 (31) | 21 (43) |
| Tumor location, n (%) | ||
| Head | 29 (57) | 25 (51) |
| Body or tail | 22 (43) | 24 (49) |
| Nodal statusa, n (%) | ||
| N0 | 40 (78) | 36 (73) |
| N1 | 11 (22) | 13 (27) |
| Biliary drainage, n (%) | ||
| No | 36 (71) | 35 (71) |
| Yes | 15 (29) | 14 (29) |
| CA19-9 (IU/ml), n (%) | ||
| < 1000 | 39 (76) | 37 (76) |
| ≥ 1000 | 12 (24) | 12 (24) |
ECOG PS, Eastern Cooperative Oncology Group performance status.
aAccording to the Union for International Cancer Control TNM version 7.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
